2023 Volume 13 Issue 2 Pages 91-96
The effect of polymyxin B-immobilized fiber column-direct hemoperfusion (PMX-DHP) for managing coronavirus disease (COVID-19) pneumonia has been previously reported. We performed PMX-DHP for 29 patients with COVID-19 pneumonia. Blood test results revealed significantly lower interleukin-6 and C-reactive protein levels after treatment than before treatment (p＝0.022 and p＝0.033, respectively). All 21 cases (72.4%) with decreased oxygen requirement after PMX-DHP survived regardless of disease severity, but 6 of 8 cases with increased oxygen requirement died. PMX-DHP may contribute to cytokine adsorption and improvement of respiratory status in COVID-19 pneumonia. Twelve cases developed blood circuit coagulation during PMX-DHP; in six cases, PMX-DHP was interrupted owing to circuit coagulation, suggesting the existence of coagulation disorder due to COVID-19 pneumonia. Future studies are necessary to evaluate the effectiveness of PMX-DHP in managing COVID-19 pneumonia.
